Dulamet Inhaler (200 mcg+5 mcg)/puff
Dulamet Inhaler (200 mcg+5 mcg)/puff Uses, Dosage, Side Effects, Food Interaction and all others data.
100 HFA inhaler: Each puff delivers Mometasone Furoate EP 100 microgram and Formoterol Fumarate Dihydrate EP 5 microgram from the actuator and Mometasone Furoate EP 115 microgram & Formoterol Fumarate Dihydrate EP 5.5 microgram from the valve.200 HFA inhaler: Each puff delivers Mometasone Furoate EP 200 microgram and Formoterol Fumarate Dihydrate EP 5 microgram from the actuator and Mometasone Furoate EP 225 microgram & Formoterol Fumarate Dihydrate EP 5.5 microgram from the valve.| Trade Name | Dulamet Inhaler (200 mcg+5 mcg)/puff |
| Generic | Mometasone Furoate + Formoterol Fumarate |
| Weight | (200 mcg+5 mcg)/puff |
| Type | Inhaler |
| Therapeutic Class | |
| Manufacturer | Square Pharmaceuticals Ltd. |
| Available Country | Bangladesh |
| Last Updated: | October 19, 2023 at 6:27 am |
Uses
This inhaler is used for asthma as follows: This inhaler is a prescription medicine used to control symptoms of asthma and prevent symptoms such as wheezing in people 12 years of age and older. This inhaler contains Formoterol which is a Long Acting β2 Agonist (LABA). When it is used alone increase the risk of hospitalizations and death from asthma problems. This contains an ICS and a LABA. When an ICS and LABA are used together, there is not a significant increased risk in hospitalizations and death from asthma problems. ... Read moreDulamet Inhaler (200 mcg+5 mcg)/puff is also used to associated treatment for these conditions: Allergic Rhinitis (AR), Asthma, Dermatitis, Dermatitis, Eczematous caused by superficial Fungal skin infection, Moderate to Severe Plaque Psoriasis, Polyps, Nasal, Pruritus, Psoriasis, Psoriasis, Moderate to Severe, Seasonal Allergies, Skin Diseases, Eczematous, Skin Infections
How Dulamet Inhaler (200 mcg+5 mcg)/puff works
In asthma, mometasone is believed to inhibit mast cells, eosinophils, basophils, and lymphocytes. There is also evidence of inhibition of histamine, leukotrienes, and cytokines.
Corticosteroids diffuse across cell membranes into the cytosol of cells where they bind to glucocorticoid receptors to produce their activity. Mometasone furoate has a particularly high receptor affinity compare to other corticosteroids, 22 times higher than that of dexamethasone. Mometasone furoate binding to a glucocorticoid receptor causes conformational changes in the receptor, separation from chaperones, and the receptor moves to the nucleus. Once at the nucleus, receptors dimerize and bind to a DNA sequence known as the glucocorticoid response element which either increases expression of anti-inflammatory molecules or inhibits expression of pro-inflammatory molecules (such as interleukins 4 and 5). Mometasone furoate also reduces inflammation by blocking transcription factors such as activator-protein-1 and nuclear factor kappa B (NF-kappaB).
Dosage
Dulamet Inhaler (200 mcg+5 mcg)/puff dosage
Adult and adolescent patients aged 12 Years and older: Dosage is either 2 inhalations twice daily of 200 HFA inhaler or 100 HFA inhaler. When choosing the starting dosage strength of this inhaler, consider the patients' disease severity, based on their previous asthma therapy, including the inhaled corticosteroid dosage, as well as the patients' current control of asthma symptoms and risk of future exacerbation. The maximum recommended dosage is two inhalations of 200 HFA inhaler twice daily (maximum daily dosage 800 mcg/20 mcg). After each dose of 2 puffs, rinse your mouth with water. Spit out the water. Do not swallow it. This will help to prevent thrush in your mouth or throat. Remove the cap and shake the inhaler vigorously before each use. Holding the inhaler well away from your mouth, breathe out gently (but not fully). Place the mouthpiece in your mouth and close your lips around it. After starting to breathe in slowly and deeply through your mouth, press the metal canister firmly to release the powder, and continue to breathe in. Remove the inhaler from your mouth and hold your breath for 10 seconds, or as long as it is comfortable, then breathe out slowly. If you take a second inhalation, you should wait for at least one minute before repeating steps 2, 3 and 4. After use replace the cap on the mouthpiece. Check your technique in front of a mirror from time to time, if you see a white mist during the inhalation you may not have closed your lips properly around mouthpiece, or you may not be breathing in as you press the can. This indicates failure of technique. If this happens, repeat the procedure from step 2 carefully. It is very important that the plastic mouthpiece is to be cleaned regularly to prevent build-up of spare powder. Remove the metal canister and wash the plastic mouthpiece in warm water at least twice a week. Leave to dry in a warm place overnight. No harm will come with from washing the mouthpiece every day. For further assistance / information please consult with your physician.Side Effects
The most common side effects of this combination include inflammation of the nose and throat, inflammation of the sinuses, headache, flu, and upper respiratory infection. Other less common side-effects include: serious allergic reactions, thrush in the mouth & throat, reduces adrenal function, increase in wheezing, lower bone mineral density in osteoporosis patient, slowed growth in children, glaucoma, blurred vision & hypokalemia.Toxicity
Overdose with a mometasone furoate inhaler may occur with chronic overuse. Symptoms of chronic overuse may present as hypercorticism and adrenal suppression, and patients may not require any more treatment than monitoring.
In animal studies of pregnancy, some fetal toxic effects were seen at or above the maximum recommended human dose, though rodents are more sensitive to these effects than humans. The benefits and risks of use should be considered in pregnant patients
It is unknown if mometasone furoate is excreted in breast milk but other corticosteroids are and therefore caution should be exercised when administering to nursing mothers.
Safety and effectiveness in pediatric populations has been established through clinical trials, though there may be a reduction in expected growth of about 1cm per year depending on the dose and duration of treatment. Pediatric patients should be titrated to the lowest effective dose for mometasone furoate inhalers.
A trial of geriatric patients showed no difference in safety or efficacy compared to younger patients, however patients of an even greater age may still be more sensitive to mometasone furoate.
The use of a mometasone furoate inhaler in moderate or severe hepatic impairment rarely leads to detectable plasma concentrations though caution may be prudent with increasing degrees of severity.
The effects of mometasone furoate in renal impairment, and across gender and race have not been studied.
Precaution
Thyrotoxicosis; severe CV disorders e.g. ischaemic heart disease, tachyarrhythmias or severe heart burn; prolonged QT-interval. DM; pregnancy; lactation; children, do not initiate or increase the dose during an exacerbation. May produce paradoxical bronchospasm.Interaction
Strong cytochrome P450 3A4 inhibitors: Use with caution. May cause increased systemic corticosteroid effects. Adrenergic agents: Use with caution. Additional adrenergic drugs may potentiate sympathetic effects Xanthine derivatives and diuretics: Use with caution. May potentiate ECG changes and/or hypokalemia. MAO inhibitors, tricyclic antidepressants, macrolides, and drugs that prolong QTc interval: Use with extreme caution. May potentiate effect on the cardiovascular system. Beta-blockers: Use with caution and only when medically necessary. May decrease effectiveness and produce severe bronchospasm. Halogenated hydrocarbons: There is an elevated risk of arrhythmias in patients receiving concomitant anesthesia with halogenated hydrocarbons.Volume of Distribution
Steady state volume of distribution of 152L.
Elimination Route
["\"Official drug label\" href=\"#label-reference","Label<\/a> but studies of repeat doses of inhaled corticosteroids suggest a bioavailability of 11%. The 0.1% ointment may have a bioavailability of 0.7%.<\/p>\n"]Half Life
The terminal half life of an inhaled dose is approximately 5 hours though it has been reported as 5.8 hours by other sources.
Clearance
The clearance rate of mometasone furoate is not readily available, though it may be close to 90L/h.
Elimination Route
For an inhaled dose, approximately 74% is excreted in the feces and 8% is excreted in the urine.
Pregnancy & Breastfeeding use
The use of this combination during pregnancy and lactation should be restricted to those patients in whom the benefits clearly outweigh the risk.Contraindication
This combination is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. This combination is contraindicated in patients with known hypersensitivity to Mometasone Furoate, Formoterol Fumarate, or any of the ingredients in this combination.Special Warning
Hepatic/Renal Impairment: There are no data regarding the specific use of this combination in patients with hepatic or renal impairment.Geriatrics: The pharmacokinetics of this combination have not been specifically studied in the elderly population.Storage Condition
Keep out of the reach of children. Store below 30°C protected from direct sunlight and heat. Keep away from contact of eyes. The container should not be punctured, broken or burnt even when apparently empty.Innovators Monograph
You find simplified version here Dulamet Inhaler (200 mcg+5 mcg)/puff
